Sohag university faculty of medicine
Sohag, Egypt
Location status: Recruiting
Location contact
Magdy M Amin, Professor
CONTACT
NCT Number: NCT07144332
Background: Uricemia dramatically rises with the stage of chronic kidney disease (CKD) and correlates with its mortality. Hemodialysis (HD) being the most used treatment at the end stage kidney disease in Sohag governorate , we sought to evaluate its efficacy on the clearance of uric acid (UAc) when used alone and twice per week.
Methods: A cross-sectional study of all consenting patients with CKD stage 5 recruited at random during hemodialysis sessions at hemodialysis unit in Sohag university hospital from July to December 2025. We collected socio-demographic data, relevant clinical information, hemodialysis related variables, and measured serum uric acid (SUA) levels before and after the dialysis to assess the uric acid clearance. A clearance between 65 and 80% and above 80% was considered as low and good efficacy of hemodialysis respectively
Interested in participating?
Request Info18 year and older
All sexes
Observational
Sohag, Egypt
Location status: Recruiting
Magdy M Amin, Professor
CONTACT
Aim of the the work The aim of this study is to estimate the efficacy of Hemodialysis alone for uric acid clearance in patients on hemodialysis. In order to evaluate the need of adjuvant uric acid lowering therapy
Patients And Methods
Prospective cross-sectional study.
Sohag University Hospital, department of Internal Medicine and hemodialysis unit.
Informed Written consent will be taken from all patients to include their data in the study, the research will be approved by medical ethics committee of Faculty of Medicine, Sohag university
Patients:
Inclusion criteria
Exclusion criteria
Number of Patients:
The study will include 100 hemodialysis patients for duration of 6 months.
The size of the dialysis membrane was estimated according to the total body surface of the patient . Membranes sizes FX60 were used for a body surface of approximately (1.2-1.5 m2 ) ; whereas FX80 between (1.6 and 1.8m2 ) and FX100 were used for body surfaces above 1.8m2.
Dialysis adequacy was calculated from the formula Kt/ V urea; K being the clearance of urea given by the dialyzer, t the duration of the dialysis session (4 h) and V the distribution volume of urea [10].
Uric acid clearance (UAc) was estimated using the formula: UAc=100 x (SUA levels before HD-SUA levels after HD) / SUA levels before HD] [14]. We defined two thresholds values for UAc (65 and 80%).
A Hemodialysis session was considered to be of low efficacy if below 65% of reduction, moderate efficacy between 65 and 80% and a good efficacy above 80% of UAc . [15].
These predictors will be included:
Statistical analysis
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: during hemodialysis session 2 to 3 hours
milligrams per deciliter (mg/dL)
Contact information is provided by the study sponsor or research team.
Ali taha, Professor
CONTACT
Reham Hussien, master
CONTACT
Sohag University
Other
Assessment of the Efficacy of Hemodialysis on Uric Acid Clearance at End Stage Kidney Disease in Sohag University Hospital
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06438445
Chronic Disease, Disease Attributes
Rio de Janeiro, Brazil
View Trial DetailsNCT04671771
Chronic Disease, Chronic Renal Disease
Phoenix, Arizona, United States
View Trial DetailsNCT07123909
Anemia Associated With End Stage Renal Disease, Bronchial Diseases
Moscow, Russia
View Trial DetailsNCT06660277
Chronic Disease, Chronic Kidney Disease Requiring Chronic Dialysis
London, Ontario, Canada
View Trial Details